BridgeMD
New treatment option for Retinal Displacement After Retinal Detachment Surgery
Official title Influence of Perfluorocarbon Liquid (LIQUID) During Pars Plana Vitrectomy on Retinal Vessel Displacement in Primary Macula-involving Rhegmatogenous Retinal Detachment
ClinicalTrials.gov ID: NCT07027098
What this study is testing
- What it's testing
- Rhegmatogenous retinal detachment (RRD) is an acute, sight threatening condition, with an incidence of approximately 10 per 100,000 people. Surgical interventions for treating RRD include pars plana vitrectomy (PPV), which currently represents the main adopted surgical choice.
- Time commitment: about 6 months
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- 18 years of age, or older.
- Diagnosis of primary MIRD with posterior vitreous detachment, and fovea off (confirmed with OCT)
- Surgeons' decision that the patient is eligible for using gas as postoperative tamponade.
- The surgeon is confident to proceed with surgery with or without the use of intraoperative PFCL
You likely can't join if
- Previous RRD and/or RRD surgery in the study eye
- Decision to use adjunct scleral buckle
- Decision to use silicone oil as tamponade
- Retinal detachment with macula on
- Patients with other retinal pathologies causing permanent structural changes to the retina in the study eye, such as diabetic retinopathy (assessed...
- Previous vitreoretinal surgery in the study eye
See the full eligibility criteria
- 18 years of age, or older.
- Diagnosis of primary MIRD with posterior vitreous detachment, and fovea off (confirmed with OCT)
- Surgeons' decision that the patient is eligible for using gas as postoperative tamponade.
- The surgeon is confident to proceed with surgery with or without the use of intraoperative PFCL
- Previous RRD and/or RRD surgery in the study eye
- Decision to use adjunct scleral buckle
- Decision to use silicone oil as tamponade
- Retinal detachment with macula on
- Patients with other retinal pathologies causing permanent structural changes to the retina in the study eye, such as diabetic retinopathy (assessed above background, or any diabetic maculopathy), previous vascular...
- Previous vitreoretinal surgery in the study eye
- Inability to come for follow ups up to 3 months
- Inability to take FAF and OCT imaging due to neck stiffness or other medical issue
- Mental incapacity
- Patient is unwilling or unable to follow or comply with all study related procedures or to sign informed consent form.
- Contraindications for PFCL
- Previous enrollment in a clinical trial involving retinal diseases and/or treatments
- Media opacity leading to poor quality retinal images (not including post operative significant cataract. See section 7.11)
- Patient inability to posture following surgery
The study team makes the final eligibility decision.
Where it's taking place
- Norwich, Norfolk, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 6 months per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Norwich, Norfolk, United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.